In the long run (starting at one year after FDA approval)
In the long run (starting at one year after FDA approval) and onwards, keeping the HIV indication and partnering for commercialization will mean much bigger profits for Cytodyn and full funding for cancer and other indications out of revenue.
Selling out for $50 million and 10% means we'll have immediate funding to jumpstart trials which will probably last 16 months at most. After that we'll be running on maximum $100 million a year at most. Enough to push some trials forward but not all.
With a partnership and us getting 40%, within the first year we'll see $200 million at most, but $400 million a year thereafter. Enough to fund all trials and return a profit.
If you're looking at selling soon for a smaller profit then selling the indication is best. Longer term a partnership is a much better deal.
2
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Main Street Capital's Evolving Private Loan Portfolio Main Street Capital Corporation (NYSE: MAIN) has made remarkable strides in developing its private loan portfolio. During the fourth quarter of the year, Main Street recorded a significant increase in new loan commitments amounting to $123.4 million, alongside investments totaling $108.0 million across its portfolio....
Continue Reading
Enhancing Customer Experiences Together Reality Based Group, known for its innovative approach to improving customer experiences, is making waves in the food service industry through a new partnership with Dave's Hot Chicken. This fast-growing chain, popular for its delicious menu offerings, has recognized the value of enhancing its customer service via advanced...
Continue Reading
Jumping right in, JMIR Publications is making waves in the academic world with its latest Journal Impact Factor (JIF) triumphs. If these folks were publicly traded, you'd want a piece because they are dominating the digital health research scene like no other. Emphasizing their stronghold, 12 out of their 24 journals clinched top-quartile spots this year—a feat that's...
Continue Reading
21shares Unveils New Canton Network ETP 21shares, a prominent issuer of cryptocurrency exchange-traded products (ETPs), has made waves in the financial markets with the introduction of the 21shares Canton Network ETP (CANTN). This innovative offering enables investors to gain exposure to the Canton Coin, the native utility token within the Canton Network, an initiative...
Continue Reading
The stock market experienced mixed results recently as investors zeroed in on critical economic indicators and job reports. Amidst ongoing geopolitical tensions, particularly in the Middle East, traders were navigating through uncertainty that impacted their portfolios. Major Indices Performances: Diverging Paths The S&P 500 dropped by 0.2%, while the Dow Jones Industrial...
Continue Reading
